Trial
NCT06967987
Study Evaluating the Combination of Bemarituzumab + FLOT Chemotherapy in Perioperative Setting for Resectable Stage cT2-T4a or N+ Gastric and GEJ Adenocarcinoma Overexpressing FGFR2b
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Institut Cancerologie de l'Ouest
Collaborators
Amgen Ltd., United Kingdom
Condition
Gastric and Gastro-oesophageal Junction (GEJ) Adenocarcinomas
Intervention
Bemarituzumab + Flot regimen
Why stopped
Discontinuation of product manufacturing by the funder prior to the start of participant enrollment
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-01-21